OGT SureSeq myPanel Myeloid Fusion MRD Panel

OGT, a Sysmex Group company, has launched the SureSeq myPanel Myeloid Fusion MRD Panel — a dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML).

Genomic AML workflows traditionally cover only part of the genomic landscape, with important fusion events being potentially undetected. The NGS panel, developed in collaboration with Roswell Park Comprehensive Cancer Center using the myPanel custom service, enables the detection of AML-associated fusion events and identifies MECOM expression levels at MRD-level sensitivity, generating broader fusion insights for AML sample cohorts in a single assay.

In an initial study of clinical research samples, the SureSeq myPanel Fusion MRD NGS workflow was shown to detect key disease-associated fusion events, including BCR::ABL1 and PML::RARA in serial dilutions as low as 1% tumour cells. By providing molecular markers of residual leukaemia that can be monitored over time, fusion transcripts can support residual disease assessment, including in samples that lack an informative DNA mutation.

As part of the end-to-end SureSeq NGS workflow, OGT’s complimentary NGS analysis software, Interpret, allows laboratories to analyse, track and visualise variants, including fusion events, across multiple timepoints within a single software environment. Available through cloud and local installation options, and with options for integration of third-party tools including QIAGEN Clinical Insight (QCI) Interpret, clinical researchers can easily follow AML disease dynamics and generate key genomic insights from their NGS data.

The SureSeq myPanel Myeloid Fusion MRD Panel can be used as a standalone assay for fusion event detection or used alongside the SureSeq Myeloid MRD Plus NGS Panel for broader MRD characterisation. Together, these panels support MRD-level detection of SNVs, indels, ITDs and fusion events in AML samples, enabling researchers to expand the range of detectable variants without relying on multiple single-analyte assays.